The Author Replies:  by Weir, Matthew R.
Sirolimus: not so sparing in the
Spare-the-Nephron trial
To the Editor: We recently reviewed the article by Weir
et al,1 which looks interesting, but there were a few caveats.
First, the study was underpowered in sample size. The
targeted sample size was 170 patients per arm to achieve
a power of 0.85 and a signiﬁcance level of 0.05, but 25% of the
patients in each arm withdrew from the study.
Second, although sirolimus (SRL) may potentially decrease
calcineurin inhibitor (CNI) toxicity, the primary end point in
the mycophenolate mofetil (MMF)/SRL arm at 24 months
compared with MMF/CNI was not signiﬁcantly different,
neither in intention-to-treat analysis nor in per-protocol
analysis. In all, 27.7% of patients randomized to MMF/SRL
switched to MMF/CNI, which will emphasize the signiﬁcance
of analyzing data by per-protocol analysis. Consequently,
the primary end point at 12 months was not even signiﬁcant.
Third, the target levels of CNI were much higher than
the current targets.2 CNI-induced vasoconstriction may
decrease glomerular ﬁltration rate and signify the difference
between arms.
Fourth, the authors reported ‘there were fewer deaths and
graft losses in the MMF/SRL arm, Po0.03’, viz-a`-viz Table 4,
which showed a signiﬁcant P value for death but not for
graft loss.
Fifth, a signiﬁcant increase in the mean 24-h urine PCR in
the MMF/SRL arm at 24 months was reported. Although the
difference between the mean PCRs may look trivial, the
actual ranges of proteinuria are considerable (1.29–2.49 vs
0.34–0.74 g/day). This will magnify the risk of SRL-associated
proteinuria and explain the signiﬁcant prevalence of peri-
pheral edema in the MMF/SRL group.
To conclude, further studies are required before we
substitute MMF/CNI with the MMF/SRL regimen.
1. Weir MR, Mulgaonkar S, Chan L et al. Mycophenolate mofetil-based
immunosuppression with sirolimus in renal transplantation: a randomized,
controlled Spare-the-Nephron trial. Kidney Int 2011; 79: 897–907.
2. Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work
Group. KDIGO clinical practice guideline for the care of kidney transplant
recipients. Am J Transplant 2009; 9(Suppl 3): S1–S157.
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The Author Replies: We appreciate the opportunity to reply
to the letter1 of Drs Shamseddin and Gupta concerning our
report on the Spare-the-Nephron (STN) trial.2
The ﬁrst concern was that they felt the study was
underpowered in sample size. As noted in our methods, the
targeted sample size was 130 patients per arm, to achieve a
power of 0.85, and a signiﬁcance level of 0.05. To accom-
modate an approximate 25% of dropouts, the sample size of
170 patients per arm was targeted. Despite the dropouts
during the course of the study, the predeﬁned primary
objective of the efﬁcacy analysis, the treatment difference in
the mean percentage change in renal function from baseline
to 12 months after randomization as measured by iothala-
mate glomerular ﬁltration rate, was statistically signiﬁcant
(P¼ 0.012). The only reason to worry about power in a
clinical trial is if no statistical signiﬁcance exists, which would
then create the possibility of a type 2 error; in which case, a
larger sample size may be necessary to evaluate the possibility
of statistical signiﬁcance.
As for comment number 2, Table 4 summarizes the
reasons of treatment failures in mutually exclusive categories
in the way that patients were only counted into the category
of their ﬁrst event. Only ﬁve patients had switched at 12
months, and a total of only seven at the end of 24 months.
However, among the 41 mycophenolate mofeti (MMF)/
sirolimus (SRL) patients, who resumed calcineurin inhibitor
(CNI) at some point during the study, a majority of them had
withdrawn from the treatment period before resuming CNI,
as only seven with ‘resume CNI’ as their ﬁrst treatment failure
event. This tells us that the majority of the switching was
due to safety and would not alter the conclusion made
from the protocol-deﬁned primary efﬁcacy analysis: intent-to-
treat analysis for mean percent change in measured
glomerular ﬁltration rate from baseline to 12 months post-
randomization.
Their third statement suggests that the target levels of CNI
were much higher than current targets. It is important to note
that in this trial, the individual transplant centers decided on
CNI levels given their unique blend of patients and level of
immunologic risk. Hence, our observations provide more
perspective with regard to center-based approaches to provide
immunosuppression for their patients.
In Table 4, the individual graft loss differences of three in
the MMF/SRL and six in the MMF/CNI group was not
different; however, when one looks at the composite of graft
loss and death, with three events in the MMF/SRL group and
11 events in the MMF/CNI group, this was statistically
signiﬁcant with a P-value o0.03.
Finally, they note that there is a signiﬁcant increase in the
mean 24-h urine protein to creatinine ratio (from 0.2±0.38
to 0.6±1.89) in the MMF/SRL group at 24 months, whereas
there is not much change in the MMF/CNI group, which
changed from 0.2±0.23 to 0.2±0.54. We are not sure where
they derived their ranges of proteinuria in the letter.
We would agree that the longitudinal change in proteinuria
in the MMF/SRL group requires more follow-up to see if it
correlates with potential changes in renal function. However,
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the clinical signiﬁcance of this change at this time remains
unknown.
Drs Shamseddin and Gupta suggest that further studies are
required before we ‘substitute MMF/CNI with the MMF/SRL
regimen’. We would agree that no immunosuppressive
regimen is right for everyone. We believe that, given the
similarity of results from the STN experience in the United
States and the results of the CONCEPT3 study conducted in
France, these two regimens, for at least the ﬁrst 2 years post-
transplant, were therapeutically equivalent, albeit with a
different side effect proﬁle. What will be important is
longitudinal follow-up of these two studies in order to
validate the durability of these 2-year observations. As with
any form of chronic immunosuppression, there is a learning
curve that takes many years. Fortunately, given the results of
studies such as CONCEPT and STN, we have a better picture
as to how best to incorporate the use of mammalian target of
rapamycin inhibitors during the ﬁrst 2 years post-transplan-
tation. We thank Drs Shamseddin and Gupta for their critical
comments.
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Does renalase degrade
catecholamines?
To the Editor: Wu et al.1 recently reported that renalase
deﬁciency alone is associated with hypertension and suscept-
ibility to ischemic myocardial damage. They contend that
renalase’s cardioprotective effects are mediated by its ability to
metabolize catecholamines. The hypothesis that renalase could
degrade catecholamines was ﬁrst proposed given its moderate
sequence homology to monoamine oxidases.2 However, it is
our opinion that no concrete evidence exists in the literature
to directly support this hypothesis. Wu et al.1 refer to the
publication2 that ﬁrst observed potential catecholamine-
degrading activity for renalase. However, the methodology
employed to arrive at this observation has been questioned.3
Furthermore, the rate of catecholamine degradation was
thought to be too low to be ascribed to enzymatic activity.3
Recently, Pandini et al.4 showed that structurally sound
recombinant renalase did not metabolize catecholamines.
The renalase-deﬁcient mice studied by Wu et al.1 were
generated from C5BL/6 mice. Nucleotide sequences encoding
renalase in wild type (C57BL/6) published at Ensembl and
NCBI do not encode proteins with ﬂavin adenosine
dinucleotide or nicotinamide adenine dinucleotide-binding
sites. Our own sequencing of renalase transcripts
from various mouse strains demonstrates that renalase in
these animals is shorter than rat and human renalase and
does not contain the N-terminal ﬂavin adenosine dinucleo-
tide-binding site characterized by a GxGxxG motif, as
described by Wu et al.1 It would have been informative for
the authors to provide a sequence alignment of C5BL/6
renalase and human renalase to illustrate this point. It is
difﬁcult to comprehend how renalase normally functions in
mice if the protein does not possess this supposedly essential
active site.
Although renalase may well have an important physiolo-
gical role in the context of hypertension and cardio-renal
disease, this appears unlikely to be mediated by degradation
of catecholamines.
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The Author Replies: Eikelis et al.1 suggest that the cardiac
and hypertensive phenotype of the renalase knockout (KO)
mouse2 is unlikely to be mediated by renalase’s ability to
metabolize catecholamines, and also question the notion that
renalase metabolizes catecholamines.
The renalase KO was maintained on a mixed background
(129Sv/J and C5BL/6) as detailed in the Materials and
Methods section. Sequence analysis of 129Sv/J genomic DNA
revealed the presence of the N-terminal ﬂavin adenine
dinucleotide-binding site of renalase. Additionally, comple-
mentary DNA sequence from NOD (EMBL-Bank:
AK170321.1) and Kunming (EMBL-Bank: DQ788834.1)
mouse strains conﬁrm the presence of the ﬂavin adenine
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